Cytiva announced that it had completed the renovation and expansion of its ‘Fast Trak’ contract biomanufacturing and process development site in Marlborough, US.
After the expansion, the facility now covers 60,00-square-feet of space and has the bioprocessing capacity to move from 10L to 2,000L scale. The services will be utilized to progress drug candidates through preclinical work onto Phase II.
Olivier Loeillot, SVP of BioProcess at Cytiva, explained that the facility will primarily serve small- to mid-size companies aiming to expedite processes, with biotech companies working to outsource manufacture to access expertise and capacity.
The upgraded site will feature an automated platform that is able to gather data to improve efficiency through the upstream and downstream process, the company stated.
In addition to providing the contract services for biomanufacturing, the company outlined that any company using its Fast Trak facility would be able to place staff members in the plant, with Cytiva’s scientists providing training on the manufacturing process.
Cytiva was created earlier this year, after Danaher acquired GE Life Sciences for $21bn (€18.6bn) and the resulting business unit took on the new moniker.
Since that time, the company has provided an update on its services for cell therapies, by offering a shipping system specifically designed for this kind of treatment, as it pivots to the growing pipeline of cell and gene therapies.
